Generative AI in drug repurposing and biomarker discovery: a multimodal approach
Frontiers in Bioinformatics · 20.03.2026 · 6
DOI: 10.3389/fbinf.2026.1755412 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioinformatics, online erschienen am 20.03.2026. Verfasst von K Saranya und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computer Science & Engineering, Bannari Amman Institute of Technology, Erode, Tamilnadu, India. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Computational drug repurposing has been widely explored using similarity-based methods, network diffusion, matrix factorization, deep learning, and graph neural networks (GNNs). However, recent heterogeneous GNN models, such as TxGNN and GAT-based models, demonstrate serious limitations for real-world biomedical applications, including poor generalization to sparsely annotated diseases, limited disease-level adaptation, and inability to effectively combine heterogeneous evidence from curated databases, multi-omics profiles, and unstructured biomedical literature.
Methods
This article proposes a heterogeneous attention-based meta-learning graph neural network named HAMGNN, which employs three major innovations: (i) relation-sensitive multi-head attention to prioritize biologically significant interactions among heterogeneous edge types, (ii) a disease-focused meta-learning framework enabling rapid adaptation to newly observed or under-informed diseases, and (iii) a literature-enhanced knowledge graph construction pipeline encoding high-confidence, LLM-extracted therapeutic information. The model was tested on a large multimodal biomedical knowledge graph assembled from DrugBank, DisGeNET, and Hetionet, comprising more than 2.2 million edges, using a stringent disjoint disease-based (cold-start) evaluation protocol.
Results
HAMGNN achieved a receiver operating characteristic–area under the curve (ROC–AUC) of 0.98 and precision of 0.95, representing a 10%–15% improvement over TxGNN and GAT-GNN on unseen disease generalization. Translational applicability was demonstrated through Alzheimer’s disease and Long COVID case studies, identifying clinically plausible repurposing candidates and disease-associated biomarker signatures via mechanistic pathways.
Discussion
HAMGNN offers a generalized, biologically grounded, and unified framework for evidence-based drug repurposing and biomarker discovery in complex and emerging diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Computer Science & Engineering, Bannari Amman Institute of Technology, Erode, Tamilnadu, India.
- Centre for Advanced Analytics, Multimedia University, Melaka, Malaysia.
- Faculty of Engineering and Technology Centre for Advanced Analytics, OE of Artificial Intelligence, Multimedia University, Melaka, Malaysia.
- Faculty of Information Science and Technology, Multimedia University, Melaka, Malaysia.
- Department of Computer Science and Engineering, Bannari Amman Institute of Technology, Sathyamangalam, Tamilnadu, India.
Zitieren
APA
Saranya, K., Joseph, E. R., Kalaiarasi, T., & Karthiga, M. (2026). Generative AI in drug repurposing and biomarker discovery: a multimodal approach. Frontiers in Bioinformatics, 6. https://doi.org/10.3389/fbinf.2026.1755412
Vancouver
Saranya K, Joseph ER, Kalaiarasi T, Karthiga M. Generative AI in drug repurposing and biomarker discovery: a multimodal approach. Frontiers in Bioinformatics. 2026;6. doi:10.3389/fbinf.2026.1755412
BibTeX
@article{Saranya2026,
author = {Saranya, K and Joseph, Emerson Raja and Kalaiarasi, Ts and Karthiga, M},
title = {Generative AI in drug repurposing and biomarker discovery: a multimodal approach},
journal = {Frontiers in Bioinformatics},
year = {2026},
volume = {6},
doi = {10.3389/fbinf.2026.1755412}
}
EUVIMED